A multicenter prospective evaluation of owner medication adherence for feline cardiovascular disease in the referral setting

Murphy, Lisa; Wang, Maria L.; O’Malley, Brian; Schrope, Donald P.; Allen, Justin W.; Chapel, Emily H.; Russell, Nicholas J.; Zimmerman, Sarah A.; Sloan, Caroline Q.; Nakamura, Reid K.

doi:10.1016/j.jvc.2022.06.007

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As atenolol affects not only the left ventricular but also the left atrial systolic function, it could facilitate thrombus formation; however, this is not thought to be clinically relevant [ 24 , 25 , 26 ]. More importantly, life-long, two-times-a-day oral medication of a cat can have a major impact on the quality of life of both the owner and the cat [ 21 , 27 , 28 ]. This should be considered when deciding whether to recommend a life-long therapy, as 22% of the owners in the present study found pilling their cats sometimes difficult or too stressful and 13%, therefore, even stopped the treatment.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Prognosis of Atenolol-Responsive Systolic Anterior Motion of the Septal Mitral Valve Leaflet in Young Cats with Severe Dynamic Left Ventricular Outflow Tract Obstruction

Kortas

Szatmári

2022

Animals

View full text Add to dashboard Cite

Background: Severe dynamic left ventricular outflow tract obstruction (DLVOTO) secondary to the systolic anterior motion of the septal mitral valve leaflet (SAM) can result either from congenital mitral valve disorders or left ventricular concentric hypertrophy of any cause, in cats commonly hypertrophic cardiomyopathy (HCM). Though HCM cannot be reversed, the question remains whether atenolol can cure cats with severe DLVOTO resulting from a presumed mitral valve dysplasia. Methods: In this retrospective case series, client-owned asymptomatic cats younger than 1.5 years with echocardiographic evidence of SAM and severe DLVOTO were included. Oral atenolol therapy and recheck echocardiography after 2–3 months were recommended. The owners and referring veterinarians were called for long-term follow-up information. Results: Of the 28 included cats, 23 were treated with atenolol. Recheck echocardiography performed in 17 cats showed a resolution of SAM in 47%. In the long term, SAM remained absent in only 9% of the treated cats. Cardiac-related death occurred in 26% of the atenolol-treated cats. Conclusions: The long term benefit of twice-daily atenolol therapy was documented in 9% of cats. Whether the cats where atenolol failed to resolve DLVOTO on long-term had HCM, or a therapy-resistant congenital primary mitral valve disorder remains unclear.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and Prognosis of Atenolol-Responsive Systolic Anterior Motion of the Septal Mitral Valve Leaflet in Young Cats with Severe Dynamic Left Ventricular Outflow Tract Obstruction

Kortas

Szatmári

2022

Animals

View full text Add to dashboard Cite

show abstract

Developmental lung disease in a cat associated with high probability of severe pulmonary hypertension: natural history, histopathology and genetic analysis

Nebel,

Williams,

Lyons

et al. 2024

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summary This report describes the diagnostic findings, natural history and genetic analysis of the candidate gene Forkhead Box F1 ( FOXF1) in a young cat with developmental lung disease and high probability of pulmonary hypertension. A 1-year-old male entire Chartreux cat was referred for cardiac murmur investigation and exercise intolerance. Echocardiography identified a high-velocity tricuspid regurgitant jet with right-sided cardiac changes, supporting a high probability of pulmonary hypertension. No congenital cardiac shunts or left-sided cardiac changes were found to support a primary cardiac cause of pulmonary hypertension. Extensive laboratory work, thoracic radiographs and CT were performed. Histopathological characterisation (lung biopsy and later post mortem) was necessary to reach the final diagnosis. Eight months after diagnosis, the cat developed right-sided congestive heart failure, eventually leading to euthanasia. Survival from diagnosis to death was 12 months. Relevance and novel information Developmental lung disease belongs to a group of diffuse lung diseases in humans associated with pulmonary hypertension. The veterinary literature describing lung growth disorders in cats is sparse, and the present report provides information on clinical presentation and progression alongside a thorough diagnostic workup, which may aid clinicians in identifying this condition. Lung biopsy was pivotal in reaching the final diagnosis. No causal variants in FOXF1 were identified.

show abstract

A multicenter prospective evaluation of owner medication adherence for feline cardiovascular disease in the referral setting

Cited by 2 publications

References 16 publications

Prevalence and Prognosis of Atenolol-Responsive Systolic Anterior Motion of the Septal Mitral Valve Leaflet in Young Cats with Severe Dynamic Left Ventricular Outflow Tract Obstruction

Prevalence and Prognosis of Atenolol-Responsive Systolic Anterior Motion of the Septal Mitral Valve Leaflet in Young Cats with Severe Dynamic Left Ventricular Outflow Tract Obstruction

Developmental lung disease in a cat associated with high probability of severe pulmonary hypertension: natural history, histopathology and genetic analysis

Contact Info

Product

Resources

About